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The aim of the present study was to assess the relationship, between Vitamin D deficiency and uterine 
leiomyoma in Congolese women. 
From April 1 to October 31, 2014, 216 patients with ultrasound diagnosis of uterine leiomyoma (cases) and 216 
women without this condition (controls) recruited in six medical facilities in Kinshasa were enrolled in the 
present study. A single blood sample was obtained from all participants to assess serum17β-estradiol and 
progesterone concentration using RIA and 25(OH) D by IRMA. Vitamin D deficiency was defined as 25(OH) D 
levels <4 ng/mL and <12 ng/mL using local and IOM cut-off levels, respectively. Chi square, Student t and 
Mann Whitney tests were used for group comparison. Logistic regression analysis was used to identify factors 
associated with Vitamin D deficiency. Vitamin D deficiency was observed in 17.1% and 47.7% of patients with 
ULM using local and IOM criteria defining different steps of vitamin D respectively. Compared to controls, the 
difference was statistically significant only when using local criteria (17.7% vs 10.2%; p = 0.028). 
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ULM main risk factors were age ≥35 years (aOR=2,974; 95%CI 1,702-5,139; p = 0,001); null parity 
(aOR=3,951;95%CI 2,311-6,754;  p= 0,001). Familial history of ULM (aOR=2,619; 95% CI 1,376-4,986; p 
=0,003) personal history of ULM a(OR3,776; 95% CI 1,885-7,565;  p=0,001); absence of menopause(OR5,502; 
95% CI 2,615-11,517; p= 0,001); high serum progesterone levels (aOR 2,320 95% CI1,136-4,711; p= 0,021),   
alcohol consumption  (aOR0,295; 95 % CI 0,150-0,580; p= 0,001) and Vitamin D deficiency(aOR2,153; 95% 
CI 1,035-4,517; p=  0,040).  Vitamin D deficiency was a common finding in patients with ULM and emerged as 
one of the main risk factors. However, this relationship need to be confirmed with a representative sample of 
women with ULM. 
Key Words: Vitamin D Deficiency; Uterine Leiomyoma; Congolese Women. 
1. Introduction 
Uterine leiomyoma (ULM) is the most common benign gynecologic condition worldwide [1,2]. ULM has-been 
reported to be three times more common among women of African descent and characterized by earlier age of 
onset, greater severity of symptoms, and different response to treatment as well as frequent treatment 
complications [3]. By the age of 50 years, the cumulative incidence of ULM is approximately 70% in white 
women and more than 80% in black women based on ultrasound detection of fibroids [1]. The main 
complications of ULM are pelvic pain, hemorrhage, early pregnancy loss and infertility [1,3]. ULM is the 
number one gynecological reason of hospitalization and the first indication of hysterectomy [4,5].Except 
hysterectomy, medical treatment and myomectomy are associated with high risk of recidivism [6]. Furthermore, 
direct costs for ULM and related care are high and represent a major burden on the health-care system [7]. For 
all the above mentioned reasons, prevention, early diagnosis and management appear as the appropriate and 
effective strategy to alleviate the health, social and economic burden of ULM leiomyoma, especially in at-risk 
black women. However, the implementation of such strategy implies the prior identification and control of 
potential associated risk factors [3].  
The pathogenesis of ULM remains is poorly understood and requires the continuous search of molecular 
mechanisms underlying ULM development and the potential risk factors as well as the influence of race [8]. In 
this regard, the rapid progression of ULM during reproductive years and its regression after menopause indicate 
that estrogen and progesterone play a key role as a growth-promoting factor that modulates the expression of 
genes involved in cellular differentiation, growth, apoptosis and extracellular matrix metabolism [8]. Besides 
genetic predisposition, the main risk factors associated with ULM include race, age, earlier menarche, parity, 
oral contraception and traditional risk factors such as obesity, hypertension, alcohol intake, smoking and 
diabetes mellitus [3, 8]. However, all these risk factors do not fully explain the increasing risk of leiomyoma 
highlighting the need for the search for new potential risk factors contributing to the development and 
progression of ULM. 
In this regard, several in vitro studies have shown that vitamin D [(25(OH) D] can inhibit the proliferation of 
uterine leiomyoma [8, 9, 10, 11, 12]. Recent epidemiological studies reported an association between low 
vitamin D levels and the risk of ULM [13, 14, 15, 16]. Recent data showed significant association between 
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lower serum vitamin D levels and ULM among different ethnic groups, especially in black women [14,15].  
Further analysis showed negative correlation between serum vitamin D levels and ULM size (r = − 0.42; p 
<0.001) among black individuals [17].  Vitamin D deficiency is estimated to be 10 times more common in 
African American women (40%) compared with white (4%) and could partially explain the white-black 
differences in the pathogenesis and clinical manifestations of ULM [15].Bearing in mind the above findings, one 
can expect vitamin D supplementation to be a one of the means for preventing or at least, for improving the 
course of ULM [18]. ULM as well as low vitamin D levels are   prevalent in black women [3, 19] however, 
studies assessing the relationship between these two conditions are scarce.    
In the Democratic Republic of the Congo (DRC), ULM is a condition frequently encountered in the daily 
gynecological practice and is one of the main indications of hysterectomy [4]. If the relationship between 
vitamin D levels and the risk of breast cancer has already been established [20], this is not the case for ULM. 
The   present case-control study aimed to establish, if any, the relationship between vitamin D status and the risk 
of ULM among black women seeking care in the hospital settings in Kinshasa, the Democratic Republic of 
Congo.  
2. Materials and Methods 
From April 1 to October 3, 2014, 432 participants were recruited from six hospitals in Kinshasa, the capital City 
of the Democratic Republic of Congo (DRC) to evaluate the association between low level of 25(OH) D and 
risk of uterine leiomyoma. Kinshasa is a city located in the NORTHERN WESTERN region of DRC (latitude 
4°19, 39” SOUTH and longitude 15°18, 48” EAST). The current study was performed during the dry season, 
during which time the city has an average of 5 hours of daily sunlight and mean temperature of 24, 4 degrees.  
A sample size of 216 cases and 216 controls was assessed to provide more than 80% power to detect a 
significant difference (α = 0.05) across groups in circulating 25(OH) D concentrations. Informed oral consent 
was obtained from all participants. All women aged 15 years or older   with an ultrasound diagnosis of ULM   
(cases)   and a sample women free of ULM   (controls) were enrolled in the present study.  Pregnant women and 
patients with chronic disorders (hepatic or renal) known to affect vitamin D metabolism were excluded.  
The following variables were taken into account : lifestyle (smoking, alcohol intake, physical activity),  medical 
history [personal history of ULM (PH-ULM) and family history of ULM (FH-UL), personal   and family history 
of hypertension (FH-HT), personal   and family history of diabetes mellitus (FH-DM), menopause, parity, oral 
contraception, age, age at menarche, age at first  and last birth,] .Questionnaire was administered to each 
participant during the clinic visit to determine participant characteristics. Height and weight were measured 
using a calibrated beam scale with a height scale. Body mass index (BMI) was calculated as weight (Kg)/height 
(m) ². Excessive weight as overweight or obesity were defined as BMI ≥ 25 Kg/m² and>29 Kg/m², respectively 
[21]. 
A blood sample was obtained from all 432 women (216 cases and 216 controls) to determine serum 25(OH) D, 
estradiol and progesterone concentrations. All tubes were protected from light and the specimens were 
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centrifuged at 2500 rpm for 10 minutes. The serum was separated and stored at -20°C until analyzed at the 
Regional Center of Nuclear Study of Kinshasa/University of Kinshasa. Serum 25(OH) D concentrations were 
measured using a local immunoradiometric assay (IRMA) method at the   Regional Center of Nuclear Study 
laboratory of Kinshasa; this method has been described elsewhere [22].  Briefly, serum 25(OH) D was 
particularly captured by a homemade polyclonal antibody during specimen incubation in RIA tube during two 
hours at the room temperature (25°C); captured 25(OH) D then reacted with a commercial monoclonal anti 
25(OH) D antibody labeled with Iodine-125. Using local laboratory cutoffs, vitamin D insufficiency and 
deficiency was defined as 25(OH)D values of 4-14 ng/ml and ˂ 4 ng/ml, respectively; vitamin D sufficiency as 
≥15ng/ml [23]. Institute of Medicine (IOM) criteria were also used to defined vitamin D deficiency, 
insufficiency and sufficiency as 25(OH)D values of <12 ng/mL, 12–19 ng/mL and  ≥20 ng/ml, respectively [24]. 
Radioimmunoassay was used to determine serum estradiol (17β-estradiol) and progesterone levels at the 
Division of Hormonology of the same laboratory. Normal range estradiol and progesterone levels were defined 
according to patient’s reproductive life cycle and 17β estradiol and progesterone kit maker cut-off points as 
follows: for 17β-Estradiol: follicular phase (57-227pg/ml); ovulation phase (127-476 pg./ml); luteal phase (77-
476pg/ml); menopause (15-75pg/ml) [25] and progesterone: follicular phase(0-1,3ng/ml);ovulation phase(0-
1,4ng/ml);luteal phase(3,4-23,5ng/ml);menopause(15-75ng/ml) [26]. 
Statistical analyses were performed using Excel 12.0 and SPSS 21 statistical software’s. Demographic, clinical 
and biological characteristics for cases and controls were evaluated using descriptive statistics: mean, standard 
deviation (SD), median and interquartile range and frequencies, as appropriate. Chi square, Student t and Mann 
Whitney tests were used to compare categorical, continuous normally and non-normally distributed variables, 
respectively. Stepwise logistic regression analysis was used to identify correlated of ULM. Were considered for 
inclusion into the model the following variables: age, parity, personal and family history of uterine leiomyoma, 
personal and family history of hypertension, personal and family history of diabetes mellitus, alcohol intake, 
menstrual cycle, body mass index (BMI), 17β-estradiol and progesterone levels, and vitamin D level. All 
variables associated with the outcome in univariate analysis were included in a multivariate analysis.  P value ≤ 
0.05 defined the level of statistical significance. The study received the clearance of the Ethical Committee of 
Kinshasa School of Public Health/University of Kinshasa (ESP/CE/N°028/2013). 
3. Results  
Table 1: Demographic, and clinical characteristics of the study population as a whole and according to uterine 
leiomyoma status. 
Characteristic          N            All (432) Cases Controls P value 
Age (years) 37,48 ± 
10,52 
37,78 ± 8,22 37,20 ± 12,36 0,576 
Age at Menarche               13,60 ±  2,55 13,66± 2,34 13,66±2,75 0,995 
Age at first delivery          20,11± 8,27 21, 31 ± 8,25 19,39 ± 8,23 0,088 
Age at last delivery           29,59 ± 7,27 29,66 ± 6,90 29,56± 7,51 0,920 
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Education (%)3     0,000 
Primary or less                              5, 6 3, 7 7, 4  
Secondary    54,4 49,1 60,6  
University 38,1 46,3 31,9  
Parity 3(2-3) 2(2-3) 3(2-3.5) 0.046 
0                                              182 8 64 0,000 
≥1                                             235 93 142  
Menopause (%)                                                                                                             0,000 
Yes 7,2 1,9 12,5  
No 92,8 98,1 87,5  
History of ULM (%)                                                                                                                                                                                       
In mother                                       5,8 5,1 6,5 0,681 
In sister                                        19,0 25,0 13,0 0,001 
Personal 6,9 27,3 6,5 0,000 
History of HT (%)                                                                                                                                                                           
In parent                                      35,4 34,3 36,6 0,687 
In brother or sister                       24,3 25,5 23,1 0,654 
Personal   16,9 19,0 14,8 0,250 
History of DM (%)                                                                                                                                                                                  
In parent                                      15,0 17,1 13,0 0,282 
In brother or sister                       11,3 13,0 9,7 0,363 
Personal   4,2 4,2 4,2 1,000 
OP7 oral contraception                                                                                                                                                                           
Yes (%)                                            6,7 5,1 8,3 0,248 
Current smoking (%)                                                                                                                                                                    
Yes (%)                                            0,7 - - - 
Alcohol intake (%)                                                                                                                                                                                        
Yes (%)                                         17,1 8,3 25,9 0,000 
Physical Activity (%)                                                                                                                                                                           
Yes (%)                                         3,9 2,3 5,6 0,135 
BMI (kg/m2)                            25,22± 5,19 25,81±  5,18 24,66  ±5,16 0,025 
Excess weight, %                                                                                                                                                                                                   
Yes 42,1 37,5 46,8  
No 41,7 45,8 46,8  
Data are expressed as mean ± SD or relative frequency in percent. Abbreviations: ULM, uterine leiomyoma; 
HT, hypertension; DM, diabetes mellitus; BMI, body mass index. 
The table below show that  the mean age of the study population was 37 ± 10 years while the BMI mean was 
25.2 ± 5 Kg/m², Their median parity was 3(2-3).   7,2% of women in the sample were already at the menopause 
stage Oral contraception, personal   and family history of leiomyoma were reported by 6, 7%;6, 9% and 24, 8% 




Compared to controls, cases (BMI = 25.8±5, 18 Kg/m2) had higher BMI than controls (BMI=24 ± 5 Kg/m²; p = 
0.025) and lower parity [2(2-3)] vs [3(2-3.5), p=0,046]. Personal history of uterine leiomyoma was higher in 
cases than controls (27, 3% vs 6, 5%, p=0,000), even for history of uterine leiomyoma in sister (25 vs 13%, 
p=0,001) and high education (46, 3% vs 31, 9%). Menopause was lower in cases than controls (1, 9% vs 12, 
5%, p=0,000). Alcohol intake was lower incases than controls (8, 3% vs 25, 9%, p=0,000).The differences 
observed in others variables were not statistically significant. 
Tableau2: Biologicals characteristics of the study population as a whole and according to uterine leiomyoma 
status. 
Characteristic   N    ALL (n=432) CASES (n=216) CONTROLS 
(n=216) 
P value2 
25(OH)D, ng/ml 9, 05(8-12) 9(7-13) 9, 10(8-13)  
Vit D Cat/CRENK    0,028 
Deficiency 13,7 17,1 10,2  
Insufficiency 48,4 42,6 54,2  
Sufficiency 29,9 31,5 28,2  
Vit D Cat/IOM    0,419 
Deficiency 48,4 47,7 49,1  
Insufficiency 35,4 33,8 37,0  
Sufficiency 8,1 9,7 6,5  
17β-estradiol, pg/ml 93,5(85,5-108) 115(92-133) 81(68-94)  
17β-estradiol (%)                                                                                                                                                  0,053
Elevated   12,7 12,5 13,0  
Normal   57,9 59,3 56,5  
Low   19,7 22,2 17,1  
Progesterone, ng/ml 0,6(0,6-0,8) 0,9(0,6-1,1) 0,4(0,3-0,6)  
Progesterone (%)                                                                                                                                                0,047
Elevated   14,4 19,0 9,7  
Normal   68,5 67,1 69,1  
Low   7,7 8,3 6,9  
Data are expressed as mean ± SD or relative frequency in percent. Abbreviations: Vit, vitamin Cat; category 
IOM, institute of medicine; CRENK, Kinshasa Regional Nuclear Energy Center.  
From the table 2 the mean levels of serum 25(OH) D, 17ß-estradiol and progesterone in the whole group were 9, 
05 ng/ml (8-12); 93, 5pg./ml (85, 5-108); 0, 6 ng/ml (0, 6-0, 8) respectively. Vitamin D insufficiency and 
deficiency using local criteria defining different steps of vitamin D were observed in 48.4% and 13.7% of 
patients, respectively. These proportions using IOM criteria defining different steps of vitamin D were 35.4% 
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and 48.4%, respectively. Compared to controls (10.2%) when using local criteria, there were more women with 
vitamin D deficiency among cases [(17.1%) p =0,028]. Difference in proportion of vitamin D insufficiency and 
deficiency by using IOM criteria were not statistically significant. 
Table 3: Multivariate independent determinants of the risk of uterine leiomyoma 
Variable Cases 
n = 216 
Controls 
n = 216 
Crude OR 95% CI p Adjusted OR 95% CI p 
Age        
<35years                        73 98 1  1  
≥35years                      143 118 1.627(1,103-2,400) 0.014 2.974(1,722-5,139) 0.000 
Parity       
≥1                                     93 142 1  1  
0 118 64 2.815(1,885-4,205) 0.000 3.951(2,311-6,754) 0.000 
FH-ULM/sister       
No 161 179 1  1  
Yes 55 28 2.184(1.321-3.609) 0.002 2.619(1,376-4,986) 0.003 
PH- ULM       
No 156 192 1  1  
Yes 59 15 4.851(2.646-8.864) 0.000 3.776 (1,885-7,565) 0.000 
Alcohol intake       
No 198 155 1  1  
Yes 18 50 0.282 (0.158-0.502) 0.000 0.295(0,150-0,580) 0.000 
Menopause       
Yes 5 26 1  1  
No 211 190 4.142(2.247-7.633) 0.000 5.502(2,615-11,517) 0.000 
Progesterone, ng/ml       
Normal   174 196     
Elevated 42 20 2, 176(1,238-3,824) 0.007 2,320(1,136-4,711) 0.021 
25(OH) D, ng.ml       
Sufficiency   1  1  
Insufficiency   1.509(0,803-2,835) 0.201 1.390 (0,632-3,055) 0.413 
Deficiency                   37 22 2.139(1,181-3,875) 0.053 2.163(1,035-4,517) 0.040 
Abbreviations: FH, familial history  PH, personal history  ULM, uterine leiomyoma  OH, hydroxyl  D, vitamin 
D.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Table 3 shows that  the age, parity, sister’s history of ULM, personal history of ULM, absence of menopause, 
alcohol intake, progesterone and vitamin D status emerged as the main independent determinants of the risk of 
having ULM. Age ≥35 years (aOR= 2.974; 95%CI 1.722-5.139; p=0,001), null parity (aOR= 3.951; 95%CI 
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2.311-6.754; p=0,010), ULM history in the sister (aOR= 2.619; 95%CI 1. 376-4.986; p=0,003), personal history 
of ULM  (aOR= 3.776; 95% CI 1.885-7.565; p=0,001), absence of menopause (aOR= 5.502; 95% CI 2.615-
11.517; p=0.001), high serum progesterone levels (aOR= 2.320; 95% CI 1.136-4.711; p=0,021) and vitamin D 
deficiency (aOR= 2.163; 95%CI 1.035-4.517; p=0,040) were associated with 1.62, 2.81, 2.18, 4.85, 4.14, 2.17, 
1.50 and 2.13 fold increased risk of having ULM whereas alcohol intake (aOR= 0.295; 95%CI 0.150-0.580; 
p=0,001) conferred 29% lower risk.  
4. Discussion 
The main findings of the present case-control study can be summarized as follows. First, whatever the criteria 
used, vitamin D deficiency was frequently seen among patients with ULM with significantly higher proportions 
in comparison to controls when using local criteria. Second, increased age, nulliparity, personal and sister 
history of ULM, alcohol intake, menopause, high serum progesterone levels and vitamin D deficiency emerged 
as the main determinants of the risk of having ULM. 
Mean levels of Vitamin D levels were similar in cases and controls in the present study. This finding contrasts 
with data from previous studies reporting low Vitamin D levels in women with ULM. In this regard, studies 
from Italy [14], United States of America [15] and Egypt [17] reported lower Vit D levels in women with ULM 
than controls. This disparity could be explained by the small sample size used in the present study. 
Age, nulliparity, familial history of ULM, absence of menopause, high serum progesterone levels, and serum 
Vitamin D deficiency were associated with increased risk of ULM whereas alcohol intake conferred less risk. It 
has been reported that many genetic, hormonal and biological factors contribute to the development and the 
progression of ULM [27]. It is also assumed that the impact of each factor is related to its interference with the 
levels and metabolism of sex steroids and their metabolites [27]. The finding of increased risk of ULM 
associated with age, nulliparity, absence of menopause and familial history of ULM is consistent with that of 
previous reports [27, 28]. Alcohol intake appears to be paradoxically protective suggesting that a moderate 
consumption of alcohol could be protective as women are likely not be heavy consumers.   
Increased serum progesterone levels were associated with increased risk of ULM. While early research has 
mostly focused on the role of estrogen in ULM, more recent evidence points to a significant role of progesterone 
[28] Kawagushi et al [29] demonstrated that mitotic activity in ULM is significantly higher in secretory 
(progesterone-dominant) phase than in proliferative (estrogen-dominant) phase of the menstrual cycle. Estrogen 
has been reported to induce the expression of progesterone receptor in ULM. It is now admitted that 
progesterone is at least as important as estrogen for ULM development [28].    Mechanisms of progesterone on 
ULM development include cross-talk with estrogen, interaction with growth factor signaling by down regulating 
the expression of insulin like growth factor 1 (IGF-1) and up regulating that of proliferating cell nuclear antigen 
(PCNA) and epidermal growth factor (EGF), known regulator of leiomyoma cells proliferation [28].  
Vitamin D deficiency conferred increased risk of ULM in the present study. Recent evidence from 3 
independent research groups in population from North Africa, East USA and Central Europe have demonstrated 
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an association between Vitamin D and increased risk of ULM. The Al-Hendy group reported first the 
association between serum Vitamin D levels and increased susceptibility to ULM in 2012 using a cohort of 
black and white women in North Africa [17, 30]. This finding was observed in other major studies including 
Baird and his colleagues , in a cohort of women from eastern USA [15] and Paffioni and his colleagues  in 
Italian women [14]. This association does suggest that Vitamin supplementation could prevent or, at least, slow 
the progression of ULM. In this regard, Blauer and his colleagues [31] confirmed the effects of Vitamin D on 
the inhibition of human myometrial and fibroid cell growth. The anti-proliferative effect of Vitamin D is thought 
to rely upon the reduction of the expression of cell cycle regulator proteins, such as CKD1, CKD2 and CDK4, 
the activation of the caspase signaling, the reduction of the expression of the anti-apoptotic BCL2 and BCL2 
protein expression in fibroid tumors and an anti-fibrotic role in leiomyoma through modulation TGF-β signaling 
[32, 33, 34, 35, 36, 37].  
The interpretation of the results of the present study should take in account of some limitations. 
The case-control design being more prone to recall and selection biases, some of the association found could be 
spurious.  Assuming that misclassification could have been non-differential, we think that some associations 
found could be stronger than observed.   
5. Conclusion 
Vitamin D deficiency was a common finding in women with ULM and emerged as one of the main risk factors 
associated with ULM.  However, this finding needs to be confirmed with a representative sample of women 
with ULM. 
Acknowledgement 
The authors gratefully thank Medical team of Saint Joseph hospital, university clinics of Kinshasa, Monkole 
medical center, Ngaliema clinic, Chinese-Congolese hospital and clinic of angelus for their invaluable help for 
the measurement of biological parameters. The authors remain deeply indebted to MODIA ANTOINE and 
SMITH MPAKA. 
References 
[1]. Catherino WH, Eltoukhi HM, Al-Hendy. Racial and ethnic differences in the pathogenesis and clinical 
manifestation of uterine leiomyoma.SeminReprod Med., 31151:370-379, September 2013.  
[2]. Elugwaraonu O;Okojie A.I.O,Okhia O,Oyadoghan G.P.The incidence of uterus fibroid among 
reproductive age women a five years review of cases at ISTA,IRRUA,EDO,NIGERIA . Intrenational 
Journal of Basic, Applied and innovative research JJ,,2(3),55-60,2013. 
[3]. Racinet Cl. Epidémiologie, facteurs de risque et symptomatologie des myomes utérins. Med Ther Med 
gynécol endocrinol Reprod, 11,118-122,2009. 
[4].                                                                                                                                                                                                                                                                                        
Nzau.NE, Mboloko.E, Tandu-Umba NFB, Lokengo LD.Hystérectomie aux cliniques universitaires de 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 22, No  1, pp 126-137 
135 
 
Kinshasa: de 2002-2010 .Medecine de l’Afrique noire, vol.59, no 4, pp221-230, Avril 2012. 
[5]. Jacoby VL,Fujimoto VY,Giudice LC,Kuppermann M,Washington AE,. Racial and ethnic disparities in 
benign gynecologic conditions and associated surgeries.Am J Obstet Gynecol, 202(6); 514-21, Jun 
2010. 
[6]. Parker WH.Uterine myomas: management. Fertility sterility, 88,225-71, 2007. 
[7]. Carls GS,Lee DW,Ozminkowski RJ,Wang Gibson TB,Stewart E.What are the total costs of surgical 
treatment for uterine fibroids. J Woman’s health (Larchmt), 17(7):1119-32,Sep 2008. 
[8]. Cavattini A.,Di Giuseppe J.,Stortoni P.,Mntik N.,Giannubilo SR et al.Uterine Fibrisis :Pathogenesis  
and Interactions with Endometrium and Endomyometrial Junction .Obstet and Gynecology 
International ,volume 2013,(2013),Article ID 173184,http//dx.doi.org/10.1155/2013/173184. 
[9]. Sharan C.Halder SK.Thota C.Jalee T.Nair S.Al-Hendy.A. Vitamin D inhibits proliferation of human 
uterine leiomyoma cells via catechol-O-methyltransferase.Fetil Steril, 95 (1) 247-53, Jan 2011. 
[10]. Halder SK, Goodwin JS, Al-Hendy A. 1,25 Dihydroxyvitamin D3 reduces TGF-beta-induced fibrosis-
related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab, , 96(4) E754-
62,Apr 2011.                                                                                                                                                 
11. Halder SK, Osteen KG, Al-Hendy A.Vitamin D3 inhibits expression and activities of matrix 
metalloproteinases-2and-9 in human uterine fibroid cells. Hum Reprod ,[Epub ahead of print] 2013 Jun 
27. 
[11]. Halder SK, Sharan C, Al-Hendy A.1, 25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma 
tumors in the Eker rat model ..Biol Reprod ,86(4) 116,Apr 2012.                                                                                                                
[12]. Soumia,Braka.MD.,Justin S.Diamond,BS., A yman Al-Hendy,MD.,PhD., Michael 
P.Diamond,MD.,Sumilk.Holder,PhD. Role of vitamin D in uterine fibroid. Biology.Fertility and 
Sterility, Volume 104.Issue 3,Pages 698-706,September 2015. 
[13]. Paffoni A,Somigliana E,Vigano P,Benaglia L,Cardellicchio L,PagliardiniL,Papaleo E,Candian 
M,Fedele L. Vitamin D Status in Women With Uterine Leiomyomas.J Clin Endocrinol Metab ,Jul 
2013. 
[14]. Baird DD,Hill MC,Schectman JM,Hollis BW. VitaminD and risk of uterine fibroids .Epidemiology.24, 
447-53,2013. 
[15]. Ramon A Durazo,Pauline Camacho,Pascal Bovet,Terrence Forrester ,Estelle V Lambert,Jacob Plange-
Rhule,Andrew N Hoofnagle,John ALOIA.Bo.ideleTayo,LaraR Dugas,Richard Scooper,and Amy 
luke.25(OH)D in African origin populations at varying latitudes Challenges the construct of a 
physiologic norm. Am J Clin Nutr ,100,908-14,2014.  
[16]. Sabry M,Halder SK,Allah AS,Roshdy E,Rajaratman V, Al-Hendy A.Serum vitamin D3 level inversely 
correlate s with uterine fibroid volume in different ethnic groups: a cross-sectional observation 
study.Int J Womens Health.,5,93-100,2013.                                                                 
[17]. World health Organization, International Agency for Research on cancer. Vitamin D and 
Cancer,.http://www.iarc.fr/publications/pdfs-online.wrk5/Report VitD.pdf, 2008.                                                                 
[18]. Nesby-O’Dell S,Scanlon KS,Cogswell ME,Gillepsie C,Hollis BW,Looker AC,et al..Hypovitaminosis 
D prevalence and determinants among African American and white women of reproductive age: third 
National Health and Nutrition Examination Survey; 1988-1994.Am J Clin Nutr, 76:187-192, 2002.                                                                                                                                                                
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 22, No  1, pp 126-137 
136 
 
[19]. Osongo.Vitamine D et cancer du sein chez la femme congolaise de Kinshasa : mémoire de fin de 
spécialisation en gynécologie, Université de Kinshasa, Démocratic Republic of Congo, 2015. 
[20]. Calcul de l’IMC (indice de masse corporelle) :http/Santé-medecine.Commentcamarche.net/faq/5-
calcul-de-l-imc-in… 
[21]. Tshiband A, Mputu L,Tozin R, Ingala , Kiampa Solid-Phase Immuno Radio Metric Assay(IRMA) of 
25-hydroxy vitamin d and displacement from serum binding proteins for Resource –Limited Settings. 
Journal of Biomedical Engineering and Medical Devices, 1, 1,2015. 
[22]. Baer locher et al.OFSP(office fédéral de la santé publique) LMS 11 02 1500 d 500f 0i0e 400FSP02001. 
OCTOBER 2002.                                                                                                                                   
[23]. Ross AC,Masson J,Abrams SA,Aloia JF,Brannon PM,Clinton SK,Durazo-Arvizu,Gallager JC,Gallo 
RL,Jones G,et al.The 2011 report on dietary reference intakes for calcium and vitamin D from the 
institute of Medicine: what clinician need to know Clin Endocrinol Metab ,96,53-8,2011. 
[24]. Trousse Radio immunologique pour le dosage in vitro de l’Estradiol dans le serum et le plasma 
humains.PI-A21854-2014-06-03.                                                                                                    
[25]. Trousse Radio immunologique pour le dosage in vitro de la progestérone dans le sérum ou le plasma 
humain .PI-IM1188-2014-02-11. 
[26]. Moroni RM, Vieira CS, Ferraini RA, Candido-dos-Reis FS, Brilolgo.Pharmacological treatment 
Uterine fibroids. Am Med Health Sci , 4(Suppl 3),S185-S192,2014. 
[27]. Borahay MA,Al-Hendy A,Kilic GS,Boehring .Signaling pathways in leiomyoma understanding 
pathobiology and implications for therapy.Mol Med ,21(1),242-56,2015. 
[28]. Kawagushi K,et al. . Mitotic activity in uterine leiomyomas during the menstrual 
cycle.Am.J.Obstet.Gynecol., 160:637-42,1989.                                                      
[29]. Sabry M, Al-Hendy A. .Innovative oral treatments of uterine 
leiomyomata.Obstet.Gynecol.Int.2012.943635. 
[30]. Blauer M,RovioPH,Ylikomi T,Heinomen PK.Vitamin D inhibits myometrial and leiomyoma cell 
proliferation in vitro.Fertil.Steril,91(5),1919-25,May 2009.                                   
[31]. Sharan C,Halder SK,Thota C,Jalee T,Nair S,Al-Hendy A.Vitamin D inhibits proliferation of human 
uterine leiomyoma cells via cathechol-O-methyltransferase.Fertil.Steril, 95(1) ,247-53,Jan 2011.  
[32]. Halder SK,Sharan C,Al-Hendy A.1,25-dihydroxyvitamin D3 treamentshrinks uterine leiomyoma 
tumors in Eker rat model.Biol Reprod 2012 Apr 19,86(4) 116.doi 10 1095/biolreprod 111  098145  
Print 2012 Apr. 
[33]. Deeb KK, Trump DL, Johnson CS..Vitamin D Signaling pathways in cancer:potential for anticancer 
therapeutics.Nat.Rev.Cancer,2007;7,684-700,2007. 
[34]. Halder SK,Osteen KC,Al-Hendy A. 1,25 dihydroxyvitamin d3 reduces extracellular matrix-associated 
protein expression in human fibroid cells.Biol.Repro.,89,150,2013. 
[35]. Halder SK, Goodwin JS,Al-Hendy A. 1,25 dihydroxyvitamin D3 reduces TGF-beta3-induced fibroids-
related gene expression in human uterine leiomyoma cells.J.Clin.Endocrinol.Metab., 96,E754-62,2011. 
[36]. Halder  SK,Osteen KG,Al-Hendy A. Vitamin D3 inhibits expression and activities of matrix 
metalloproteases-2and -9 in human uterine fibroids cells.Hum.Reprod., 28,2407-16,2013. 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 22, No  1, pp 126-137 
137 
 
Appendix: author contributions  
PIERRE INGALA, participated in protocol elaboration, data collection and analysis and drafted the manuscript. 
ALPHONSE TSHIBAND, performed biological analysis and reviewed the manuscript 
JUSTIN MBOLOKO, participated in protocol elaboration conception and data analysis, reviewed the 
manuscript. 
FRANCOIS LEPIRA, participated in protocol elaboration conception and data analysis, reviewed the 
manuscript. 
PATRICK KAYEMBE, performed statistical analysis of data and reviewed the manuscript. 
BIENVENU LEBWAZE, participated in protocol elaboration conception and data analysis, reviewed the 
manuscript.  
ARSENE MPUTU, conceived the study, participated in data analysis and reviewed the manuscript. 
 
 
